Immunogenic comparison for two different recombinant chimeric peptides (CP12 and CP22) containing one or two copies of three linear B cell epitopes from β-hCG subunit
Immunogenic comparison for two different recombinant chimeric peptides (CP12 and CP22) containing one or two copies of three linear B cell epitopes from β-hCG subunit
复制标题
DOI：
10.1016/j.jbiotec.2010.11.003
复制
发表时间：
2011-01-10
影响因子：
4.1
通讯作者：
Xie, Yi
中科院分区：
文献类型：
--
作者：
He, Ya-ping;Xu, Wan-xiang;Xie, Yi
为了研制一种性能上级的人绒毛膜促性腺激素（hCG）嵌合肽（CP）疫苗，构建并生物合成了两种CP抗原（CP 12和CP 22），它们分别编码一个或两个拷贝的hCG β亚单位的3个线性B细胞表位和6个外源T细胞表位，包括乙型肝炎表面抗原和破伤风类毒素的两个混杂TCE。将分子量分别为21和23 kDa的hCG CP 12和CP 22插入到热诱导表达载体pBV 221中，在大肠杆菌中表达量约为细胞总蛋白的1%。具有>95%相对同质性的纯化的CP 12和CP 22蛋白是免疫原性的，并且在兔和三种不同近交系小鼠中引发针对β-hCG的β 5、β 9和β 8 BCE的抗体。在Balb/c小鼠中的小鼠子宫重量研究表明，与β-hCG的C-末端免疫原相比，具有额外β 5中和表位的CP 12和CP 22抗原增强了诱导抗体的体内生物中和能力。我们建议，生物合成的CP 22，拥有两个拷贝的三个BCE，代表了一种新的候选抗原的hCG避孕或肿瘤治疗疫苗。(C)2010爱思唯尔有限公司版权所有。
To develop a superior chimeric peptide (CP) vaccine of human chorionic gonadotropin (hCG), two CP antigens (named CP12 and CP22) encoding one or two copies of three linear B cell epitopes from the beta-hCG subunit and six foreign T cell epitopes, including two promiscuous TCEs from hepatitis B surface antigen and tetanus toxoid, were constructed and biosynthesized. The hCG CP12 and CP22 of 21 or 23 kDa, respectively, were expressed in Escherichia coli at the level of similar to 1% of total cell proteins when inserted into thermo-inducible pBV221 expression vector. The purified CP12 and CP22 proteins with >95% relative homogeneity are immunogenic, and elicited antibodies against the beta 5, beta 9 and beta 8 BCEs of beta-hCG in both rabbits and three different inbred strains of mice. A mouse uterine weight study in Balb/c mice demonstrated that the CP12 and CP22 antigens with an additional beta 5 neutralizing epitope enhanced the in vivo bio-neutralization capacity of the induced antibodies compared to the C-terminal immunogen of beta-hCG. We propose that the biosynthesized CP22, possessing with two copies of three BCEs, represents a novel candidate antigen for an hCG contraceptive or tumor therapeutic vaccine. (C) 2010 Elsevier B.V. All rights reserved.